New Topics in Vasopressin Receptors and Approach to Novel Drugs: Vasopressin and Pain Perception

Koshimizu, Taka-aki; Tsujimoto, Gozoh

doi:10.1254/jphs.08r18fm

Cited by 31 publications

(29 citation statements)

References 59 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A number of studies have reported on the analgesic actions of exogenously administered neurohypophysial hormones against different pain modalities (Lundeberg et al, 1994; Ge et al, 2002; Yu et al, 2003; Gao and Yu, 2004; Koshimizu and Tsujimoto, 2009), but little is known about the role of endogenous OXT and AVP in pain processing. The anatomical distribution of OXT and OTRs in rat strongly supports such a role.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, the actions of OXT and AVP in the CNS have received increasing attention because of the documented role of these peptides in the regulation of complex social and sexual behavior in mammals (Donaldson and Young, 2008; Young et al, 2008), including humans (Baumgartner et al, 2008; Petrovic et al, 2008; Walum et al, 2008). Concomitantly, a growing literature has demonstrated the analgesic effects of OXT and AVP in both human and rodent species (Honda and Takano, 2009; Koshimizu and Tsujimoto, 2009). Indeed, OXT was reported to be analgesic in a variety of pain tests when administered into the brain (Ge et al, 2002; Lund et al, 2002; Wang et al, 2003; Gao and Yu, 2004), the spinal cord (Yu et al, 2003; Miranda-Cardenas et al, 2006; Condes-Lara et al, 2007) or systemically (Lundeberg et al, 1994; Reeta et al, 2006).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Oxytocin-Induced Analgesia and Scratching Are Mediated by the Vasopressin-1A Receptor in the Mouse

Schorscher-Petcu¹,

Sotocinal²,

Ciura³

et al. 2010

Journal of Neuroscience

166

146

View full text Add to dashboard Cite

The neuropeptides oxytocin (OXT) and arginine vasopressin (AVP) contribute to the regulation of diverse cognitive and physiological functions including nociception. Indeed, OXT has been reported to be analgesic when administered directly into the brain, the spinal cord, or systemically. Here, we characterized the phenotype of oxytocin receptor (OTR) and vasopressin-1A receptor (V1AR) null mutant mice in a battery of pain assays. Surprisingly, OTR knock-out mice displayed a pain phenotype identical to their wild-type littermates. Moreover, systemic administration of OXT dose-dependently produced analgesia in both wild-type and OTR knock-out mice in three different assays, the radiant-heat paw withdrawal test, the von Frey test of mechanical sensitivity, and the formalin test of inflammatory nociception. In contrast, OXT-induced analgesia was completely absent in V1AR knock-out mice.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Oxytocin-Induced Analgesia and Scratching Are Mediated by the Vasopressin-1A Receptor in the Mouse

Schorscher-Petcu¹,

Sotocinal²,

Ciura³

et al. 2010

Journal of Neuroscience

166

146

View full text Add to dashboard Cite

show abstract

“…It is believed that AVP causes antinociception in both humans and animals [2,11]. The antinociceptive activity was observed after subcutaneous, intraperitoneal or intracerebroventricular administration of AVP [3,14]. In contrast, Brattleboro rats, which are naturally deficient in AVP, had a hyperalgesic state in flinch-jump threshold test and impaired stress analgesia [4].…”

Section: Introductionmentioning

confidence: 99%

Spinal vasopressin alleviates formalin-induced nociception by enhancing GABAA receptor function in mice

Peng

Qiu

et al. 2015

Neuroscience Letters

View full text Add to dashboard Cite

“…18,19 Vasopressin stimulates the secretion of β-endorphins by the hypothalamus, which could cause a central analgesic effect. 20,21 …”

Section: Discussionmentioning

confidence: 99%

Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial

Casteleijn

Blais

Chapman

et al. 2017

American Journal of Kidney Diseases

View full text Add to dashboard Cite

Background Kidney pain is a common complication in patients with autosomal dominant polycystic kidney disease (ADPKD), and data from the TEMPO 3:4 trial suggested that tolvaptan, a vasopressin V2 receptor antagonist, may have a positive effect on kidney pain in this patient group. Because pain is difficult to measure, the incidence of kidney pain leading to objective medical interventions was used in the present study to assess pain. Study Design Secondary analysis from a randomized controlled trial. Setting & Participants Patients with ADPKD with preserved kidney function. Intervention Tolvaptan or placebo. Outcomes Kidney pain events defined by objective medical interventions. Measurements Kidney pain events were recorded and independently adjudicated. Incidence of a first kidney pain event was assessed overall and categorized into 5 subgroups according to severity. Results Of 1,445 participating patients (48.4% women; mean age, 39 ± 7 [SD] years; mean estimated glomerular filtration rate, 81 ± 22 mL/min/1.73 m2; median total kidney volume, 1,692 [IQR, 750–7,555] mL), 50.9% reported a history of kidney pain at baseline. History of urinary tract infections, kidney stones, or hematuria (all P < 0.001) and female sex (P < 0.001) were significantly associated with history of kidney pain. Tolvaptan use resulted in a significantly lower incidence of kidney pain events when compared to placebo: 10.1% versus 16.8% (P < 0.001), with a risk reduction of 36% (HR, 0.64; 95% CI, 0.48–0.86). The reduction in pain event incidence by tolvaptan was found in all groups irrespective of pain severity and was independent of predisposing factors (P for interaction > 0.05). The effect of tolvaptan was explained at least in part by a decrease in incidence of urinary tract infections, kidney stones, and hematuria when compared to placebo. Limitations Trial has specific inclusion criteria for total kidney volume and kidney function. Conclusions Tolvaptan decreased the incidence of kidney pain events independent of patient characteristics predisposing for kidney pain and possibly in part due to reductions in ADPKD-related complications.

show abstract

New Topics in Vasopressin Receptors and Approach to Novel Drugs: Vasopressin and Pain Perception

Cited by 31 publications

References 59 publications

Oxytocin-Induced Analgesia and Scratching Are Mediated by the Vasopressin-1A Receptor in the Mouse

Oxytocin-Induced Analgesia and Scratching Are Mediated by the Vasopressin-1A Receptor in the Mouse

Spinal vasopressin alleviates formalin-induced nociception by enhancing GABAA receptor function in mice

Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial

Contact Info

Product

Resources

About